Recombinant Human Mitogen-Activated Protein Kinase Kinase Kinase 1, GST-Tagged

• Cat.No.: MAP3K1-1037H
• Product Overview: Recombinant human MAP3K1 (900-1748) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.

Specification

• Cat. No.: MAP3K1-1037H
• Description: MAP3K1 or MEK kinase, is a serine/threonine kinase that is downstream of mitogenic and metabolic stimuli, including insulin and many growth factors. MAP3K1 functions not only as an upstream activator of ERK and JNK through its kinase domain, but also as an E3 ligase through its PHD domain, providing a negative regulatory mechanism for decreasing ERK1/ERK2 activity by ubiquitination and degradation. MAP3K1 -/- embryonic stem cells from mice show loss or altered responses of JNK to microtubule disruption and cold stress.
• Applications: Kinase Assay, Western Blot
• Molecular Weight: 155 kDa
• Expression System: Sf9 insect cells using baculovirus.
• Species: Human
• Form: Recombinant protein stored in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10mM glutathione, 0.25 mM DTT, 0.1 mM EDTA, 0.1 mM PMSF, 25% glycerol.
• Specific Activity: 820 nmol/min/mg
• Purity: > 85 %
• Concentration: 0.1 ug/ul
• Sequences: 900-1748
• Storage: Store product at -70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
• Pathways: Activated TLR4 signalling; Apoptosis; Apoptosis Modulation by HSP70; BCR signaling pathway; CD40/CD40L signaling; Ceramide signaling pathway; EGFR1 Signaling Pathway; ErbB1 downstream signaling; FAS (CD95) signaling pathway; FAS pathway and Stress induction of HSP regulation; Fc-epsilon receptor I signaling in mast cells; GnRH signaling pathway; IFN-gamma pathway; MAPK signaling pathway; Neurotrophin signaling pathway; RIG-I-like receptor signaling pathway
• Protein length: 900-1748

Gene Information

• Gene Name: MAP3K1 mitogen-activated protein kinase kinase kinase 1 [ Homo sapiens ]
• Official Symbol: MAP3K1
• Synonyms: MAP3K1; MEKK; MEKK1; SRXY6; MAPKKK1; mitogen-activated protein kinase kinase kinase 1; MAPK/ERK kinase kinase 1; MEK kinase 1; MAP/ERK kinase kinase 1; EC 2.7.11.25
• Gene ID: 4214
• mRNA Refseq: NM_005921
• Protein Refseq: NP_005912
• MIM: 600982
• UniProt ID: Q13233
• Chromosome Location: 5q11.2
• Function: ATP binding; JUN kinase binding; JUN kinase kinase activity; JUN kinase kinase kinase activity; MAP kinase kinase kinase activity; identical protein binding; metal ion binding; mitogen-activated protein kinase binding; mitogen-activated protein kinase kinase binding; nucleotide binding; protein kinase activity; protein kinase activity; protein serine/threonine kinase activity

Reviews

12/20/2020

The bands of proteins in Western Blotting experiments were very clear.

11/10/2020

The MAP3K1 protein is highly recommended for its exceptional performance in ELISA assays.

09/30/2017

Researchers can rely on the MAP3K1 protein to deliver precise results, enhancing the credibility and efficiency of their experiments.

Q&As

How is MAP3K1 protein expression measured in clinical settings?

MAP3K1 protein expression can be measured using immunohistochemistry (IHC) or Western blotting in clinical settings.

Are there any diseases associated with MAP3K1 protein mutations?

Yes, mutations in the MAP3K1 gene have been linked to several diseases, including breast cancer, lung cancer, and colon cancer.

What are the implications of MAP3K1 protein in drug resistance?

MAP3K1 protein has been implicated in the development of drug resistance in certain cancer types, highlighting its importance in personalized medicine and treatment response.

What are the potential diagnostic applications of MAP3K1 protein analysis?

MAP3K1 protein analysis can be used for diagnostic purposes to identify specific molecular subtypes of cancer and to predict disease prognosis.

How is MAP3K1 protein targeted in precision medicine approaches?

Precision medicine approaches may involve targeting MAP3K1 protein through specific inhibitors or monoclonal antibodies to inhibit its oncogenic activity.